Commentary| Volume 5, ISSUE 5, P370, December 2004

Is Bcl-2 Useful to Select Endocrine Therapy for Breast Cancer?

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cardoso F
        • Paesmans D
        • Larsimont V
        • et al.
        Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer.
        Clin Breast Cancer. 2004; 5: 364-369
        • Gasparini G
        • Barbareschi M
        • Doglioni C
        • et al.
        Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
        Clin Cancer Res. 1995; 1: 189-198
        • Yang Q
        • Sakurai T
        • Yoshimura G
        • et al.
        Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
        Oncol Rep. 2003; 10: 121-125
        • Diel P
        • Smolnikar K
        • Michna H
        The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells.
        Breast Cancer Res Treat. 1999; 58: 87-97
        • Salami S
        • Karami-Tehrani F
        Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines.
        Clin Biochem. 2003; 36: 247-253
        • Zhang GJ
        • Kimijima I
        • Onda M
        • et al.
        Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels.
        Clin Cancer Res. 1999; 5: 2971-2977